VIEWMIND provides a reliable source of information to aid health professionals in performing accurate diagnosis. With a set of Biocognitive and Functional assessment battery, physicians are able to perform a differential diagnostic, predicting with accuracy if Mild Cognitive Impairment will eventually develop into Alzheimer’s Disease, Frontotemporal Dementia or related pathologies, years before common symptoms are visible.



Visual target processing

We measure cognitive performance during encoding, maintenance and recognition of visual targets using Eyetracking.
Analyzing a persons’ visual task processing capabilities, we are able to countercheck how executive functions, attentional resources and working memory are performing. In addition, we link the mentioned cognitive processes with the following regions of the brain:

    • Frontal Eye Fields (FEF)

    • Supplementary Eye Fields (SEF)

    • Ventrolateral Prefrontal

    • Cortex (vlPFC)

    • Dorsolateral Prefrontal Cortex (dlPFC)

    • Posterior Parietal Cortex (PPC)

    • Primary Visual Cortex (V1)

    • Anterior Cingulate Cortex (ACC)

    • Basal Ganglia (BG)

    • Superior Colliculus (SC)

    • Cerebellum (CB)

    • Ocular Motor Plant (OMP)


Reading task

We measure cognitive performance during the reading of a corpus of well-defined sentences. Reading allows us to analyze eye movement behavior when recognizing and integrating words as part of defined sentences. The Reading Task evaluation is able to measure the cognitive functioning of the attentional processes, working memory, retrieval memory, executive processes and semantic memory. We relate such functions with activities in the:

    • Prefrontal Cortex

    • Frontal Cortex

    • Temporal Lobe

    • Angular Gyrus.


Eye-movment analysis during visual short term memory performance

Using the Visual short-term memory (VSTM) task we measure eye movement behavior when binding visual targets. VSTM binding task, entails cortico-cortical interactions between areas responsible for processing features and those responsible for keeping them together in VSTM. VSTM binding declines in patients with dementia due to Alzheimer’s Disease even though they appear to be asymptomatic when performing traditional neuropsychological tasks. This evaluation can measure:

    • Angular gyrus (AG)

    • Frontal eye fields (FEF)

    • Lateral occipital complex (LOC)

    • Lateral prefrontal cortex (lPFC)

    • Medial temporal lobe (MTL)

    • Entorhinal Cortex (EC)

    • Perirhinal Cortex (PC)

    • Superior Colliculus (SC)

    • Locus coeruleus (LC)


VIEWMIND has developed a biomarker, capable of predicting the onset of the disease before any visible symptoms appear:

  • More than a decade in advance

  • In collaboration with the Heriot Watt University of Edinburgh and the recent addition to ViewMind’steam of Mario Parra, ViewMind is enhancing the Biomarker’s predictive capabilities

  • Clinical Trials in Antioquia, Colombia to test the enhanced biomarker with familial-AD patients beginning in 2018


VIEWMIND is performing studies on patients with MS to analyze the effect of drugs on their cognitive functions. MS where evaluated using:

  • Traditional Neurocognitive Evaluations


  • Neuroimaging Data Processing/FSL*


15 + 10 =

Copyright © 2018 ViewMind ­ |


Please see our Terms of Service and Privacy Policy

Copyright © 2018 ViewMind. Please see our Terms of Service and Privacy Police